Cefetamet pivoxil a new oral cephalosporin: clinical evaluation.

Cefetamet pivoxil, an oral cephalosporin, was given to 683 patients; 414 received standard antibiotics. 1.5 and 1.2 g of cefetamet pivoxil were fully effective in gonorrhea. In two trials in uncomplicated urinary tract infections (UTI) 2 g cefetamet as a single dose was significantly superior (93.3% cure) to 2 g cefadroxil (74.4% cure) and 90.8% vs. 74.7% cure. Results in complicated UTI with 2 g cefetamet for 10 days were 87.9% cure and 71.4% cure with cefadroxil. In acute exacerbation of chronic bronchitis 88% were cured with cefetamet (101 patients) and 80% with cefaclor (n = 94). In acute ear-nose-throat infections, the response rate was 89% and 93% with 1 or 2 g cefetamet per day, respectively. Adverse events were noticed in 6% of the 683 cefetamet-treated patients; they were rapidly reversible.